Levodopa Carbidopa Teva (Levodopa, Carbidopa Monohydrate)

Levodopa is converted to dopamine once it reaches the brain, compensating for the dopamine deficiency in Parkinsonian disorders. Carbidopa inhibits the peripheral enzyme that would otherwise convert levodopa outside the brain, increasing the amount that reaches the central nervous system and reducing peripheral side effects.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s disease severity, response to therapy, and individual tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for use in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson’s disease because it directly replenishes dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or in early disease, but they generally provide less robust motor improvement than levodopa combined with carbidopa.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Levodopa Carbidopa Teva is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can interfere with absorption, so spacing the dose from protein‑rich meals is often recommended.

Serious risks include the development of dyskinesias (involuntary movements), psychiatric disturbances such as hallucinations or psychosis, severe orthostatic hypotension, and rare cardiac arrhythmias. Patients should be monitored regularly for these events.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with a history of cardiac disease, severe liver impairment, or uncontrolled psychiatric illness.